Undisclosed KRAS TCR-modified T-cell therapy / Anocca - LARVOL DELTA

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire) - "MaxCyte...announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte’s Flow Electroporation technology and ExPERT platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies. Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue....Anocca recently received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility, and its lead program, targeting mutant KRAS-driven advanced pancreatic cancer, is in clinical development."

Licensing / partnership • Pancreatic Cancer